Positive Biomarker Data from Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Announced
“Leveraging the power of Comparative Oncology, we were able to train and test potentially predictive biomarkers from the Canine Metastatic Osteosarcoma Trial in order to form a hypothesis to test in a pre-specified way in the Human Metastatic Osteosarcoma Trial,” said Paul Romness, MHP, Chairman & CEO of OS Therapies. “We believe the confirmation of this pre-specified pathway analysis in humans adds significant resolution to our clinical data, increasing the clinical interpretability of the 2-year overall survival data for regulatory agencies. The confirmation of a pre-specified canine biomarker pathway being upregulated in a comparable human clinical study population leveraged canine biomarker data to a generate hypothesis that was tested in a pre-specified way and confirmed as a surrogate marker of clinical efficacy. This biomarker data strengthens our pending Biologics License Application (BLA) submission.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo